4 years ago

Brainomix Secures $21.2 Million to Expand AI Diagnostics Platform

  • Brainomix, an Oxford-based medical diagnostics company, has raised £16 million ($21.2 million) in a Series B funding round

  • The round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from new investor Tencent Holdings and existing investor Oxford University Innovation Fund

  • The funding will be used to expand Brainomix's AI-powered stroke imaging solution into new markets and adapt it for diagnosing other diseases

      • ProblemHealthcare

      "Diagnosing diseases like stroke, lung fibrosis, and cancer can be time-consuming and inaccurate, leading to delayed treatment and poor patient outcomes."

      Solution

      "Brainomix has developed an AI-powered imaging tool that analyzes medical images to detect biomarkers, providing clinicians with faster and more accurate diagnoses, leading to better treatment decisions and improved patient outcomes."

      Covered on